Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
BACKGROUND
Patients who have undergone total hip or knee replacement (THR, TKR) have a high risk of developing venous thromboembolism (VTE) following surgery, despite appropriate anticoagulation with warfarin or low molecular weight heparin (LMWH). New anticoagulants are under investigation.


OBJECTIVE
To examine the efficacy and safety of prophylactic anticoagulation with direct thrombin inhibitors (DTIs) versus LMWH or vitamin K antagonists in the prevention of VTE in patients undergoing THR or TKR.


METHODS
The Cochrane Peripheral Vascular Disease Group searched their Specialized Register (last searched 12 March 2010) and CENTRAL (last searched 2010, Issue 2).


METHODS
Randomised controlled trials.


METHODS
Three reviewers independently assessed methodological quality and extracted data in pre-designed tables. The reported follow-up events were included


RESULTS
We included 14 studies included involving 21,642 patients evaluated for efficacy and 27,360 for safety. No difference was observed in major VTE in DTIs compared with LMWH in both types of operations (odds ratio (OR) 0.91; 95% confidence interval (CI) 0.69 to 1.19), with high heterogeneity (I(2) 71%). No difference was observed with warfarin (OR 0.85; 95% CI 0.63 to 1.15) in TKR, with no heterogeneity (I(2) 0%).More total bleeding events were observed in the DTI group (in ximelagatran and dabigatran but not in desirudin) in patients subjected to THR (OR 1.40; 95% CI 1.06, 1.85; I(2) 41%) compared with LMWH. No difference was observed with warfarin in TKR (OR 1.76; 95% CI 0.91 to 3.38; I(2) 0%). All-cause mortality was higher in the DTI group when the reported follow-up events were included (OR 2.06; 95% CI 1.10 to 3.87).Studies that initiated anticoagulation before surgery showed less VTE events; those that began anticoagulation after surgery showed more VTE events in comparison with LMWH. Therefore, the effect of the DTIs compared with LMWH appears to be influenced by the time of initiation of coagulation more than the effect of the drug itself.The results obtained from sensitivity analysis, did not differ from the analysed results; this strengthens the value of the results.


CONCLUSIONS
Direct thrombin inhibitors are as effective in the prevention of major venous thromboembolism in THR or TKR as LMWH and vitamin K antagonists. However, they show higher mortality and cause more bleeding than LMWH. No severe hepatic complications were reported in the analysed studies. Use of ximelagatran is not recommended for VTE prevention in patients who have undergone orthopedic surgery. More studies are necessary regarding dabigatran.
Salazar
Carlos A
CA
Universidad Peruana Cayetano Heredia, Avenida Honorio Delgado 430, San Martin de Porres, Lima, Peru.
Malaga
German
G
Malasquez
Giuliana
G
D000925:Anticoagulants / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D001384:Azetidines; D001562:Benzimidazoles / Q000627:therapeutic use; D001596:Benzylamines; D000075202:Contraindications; D000069604:Dabigatran; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013917:Thrombin / Q000037:antagonists & inhibitors*; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D001384:Azetidines; D001562:Benzimidazoles; D001596:Benzylamines; D006495:Heparin, Low-Molecular-Weight; D011725:Pyridines; D014812:Vitamin K; C426686:ximelagatran; D014859:Warfarin; D013917:Thrombin; D000069604:Dabigatran
JAMA. 1994 Jan 5;271(1):59-63
8258890
Control Clin Trials. 1995 Feb;16(1):62-73
7743790
Cochrane Database Syst Rev. 2002;(4):CD000305
12519540
Lancet. 2002 Aug 10;360(9331):491-2; author reply 492
12241752
Circulation. 2002 Feb 26;105(8):1004-11
11864933
Thromb Haemost. 1995 Dec;74(6):1428-31
8772214
J Bone Joint Surg Am. 2001 Jun;83(6):900-6
11407799
Thromb Haemost. 2003 Feb;89(2):288-96
12574809
Anesth Analg. 2007 Dec;105(6):1540-7, table of contents
18042845
Int J Clin Pract. 2003 Jan-Feb;57(1):57-9
12587945
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
N Engl J Med. 2003 Oct 30;349(18):1703-12
14585938
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Arch Intern Med. 2002 Jul 8;162(13):1465-71
12090882
JAMA. 1993 Dec 1;270(21):2598-601
8230645
Ann Intern Med. 2002 Oct 15;137(8):648-55
12379064
J Bone Joint Surg Am. 1991 Apr;73(4):484-93
2013587
Chest. 2001 Jan;119(1 Suppl):132S-175S
11157647
Thromb Haemost. 1992 Apr 2;67(4):417-23
1321509
Thromb Haemost. 1996 Mar;75(3):407-11
8701398
Thromb Res. 2003 Jul 15;109 Suppl 1:S23-9
12818631
Arch Intern Med. 2001 Oct 8;161(18):2215-21
11575978
Isr Med Assoc J. 2004 Aug;6(8):479-81
15326828
J Bone Joint Surg Br. 1989 May;71(3):492-7
2785998
J Thromb Haemost. 2005 Jan;3(1):103-11
15634273
J Bone Joint Surg Am. 2005 Oct;87(10):2169-77
16203879
Eur J Clin Pharmacol. 2006 Mar;62(3):173-7
16416154
Ann Intern Med. 1996 Apr 1;124(7):619-26
8607589
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Thromb Haemost. 1997 Jan;77(1):32-8
9031445
J Arthroplasty. 2001 Sep;16(6):679-88
11547365
J Thromb Haemost. 2003 Oct;1(10):2119-30
14521593
Lancet. 2007 Sep 15;370(9591):949-56
17869635
Thromb Haemost. 2002 Feb;87(2):231-7
11858482
Can J Surg. 1999 Dec;42(6):457-61
10593248
J Thromb Haemost. 2007 Aug;5(8):1660-5
17663737
Curr Opin Gastroenterol. 2005 May;21(3):283-92
15818148
Chest. 2004 Sep;126(3 Suppl):338S-400S
15383478
N Engl J Med. 1997 Nov 6;337(19):1329-35
9358126
Thromb Haemost. 1996 May;75(5):706-11
8725709
Ann Intern Med. 2001 Nov 20;135(10):858-69
11712876
Lancet. 2003 Nov 22;362(9397):1691-8
14643116
J Thromb Haemost. 2006 Jan;4(1):121-8
16409461
J Clin Pharmacol. 2007 Mar;47(3):371-82
17322149
Thromb Haemost. 2004 Aug;92(2):428-30
15269843
J Arthroplasty. 1997 Sep;12(6):599-602
9306209
Chest. 2001 Jan;119(1 Suppl):22S-38S
11157641
Thromb Haemost. 2002 Apr;87(4):580-5
12008938
J Thromb Haemost. 2007 Nov;5(11):2178-85
17764540
N Engl J Med. 1993 Nov 4;329(19):1370-6
8413432
Clin Drug Investig. 2005;25(1):65-77
17523747
Arch Intern Med. 1998 Jul 27;158(14):1525-31
9679793
Arch Intern Med. 2001 Sep 10;161(16):1952-60
11525697
J Thromb Haemost. 2003 Dec;1(12):2490-6
14675083
Arch Intern Med. 1998 Apr 27;158(8):873-8
9570173
Arch Intern Med. 2003 Aug 11-25;163(15):1849-56
12912723
Clin Pharmacokinet. 2003;42(7):687-701
12844328
J Thromb Haemost. 2005 Nov;3(11):2479-86
16241946
BMJ. 1991 Dec 7;303(6815):1431-5
1773147
Hamostaseologie. 2002 Aug;22(3):21-4
12215757
Lancet. 2002 Jan 26;359(9303):294-302
11830196
Arch Intern Med. 2003 Jun 9;163(11):1362-6
12796074
JAMA. 2005 Feb 9;293(6):690-8
15701910
Thromb Res. 2002 Mar 1;105(5):371-8
12062537
JAMA. 2005 Feb 9;293(6):699-706
15701911
Thromb Res. 2002 May 1;106(3):V275-84
12356489
Chest. 2004 Sep;126(3 Suppl):265S-286S
15383475
N Engl J Med. 2003 Oct 30;349(18):1713-21
14585939
Thromb Res. 2009;123(3):488-97
18485453
Health Technol Assess. 2009 Sep;13 Suppl 2:55-62
19804690
J Arthroplasty. 2009 Jan;24(1):1-9
18534438
Chest. 1998 Nov;114(5 Suppl):531S-560S
9822062
J Am Coll Cardiol. 2003 May 7;41(9):1445-51
12742279
Lancet. 1996 Mar 9;347(9002):635-9
8596376
Lancet. 2002 Nov 9;360(9344):1441-7
12433510
Clin Orthop Relat Res. 1996 Dec;(333):27-40
8981880
Circulation. 2006 Nov 28;114(22):2374-81
17116766
BMJ. 2007 May 19;334(7602):1053-4
17510154
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Chest. 2001 Jan;119(1 Suppl):8S-21S
11157640